The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

Microbiotica, a clinical-stage biopharma company, has presented new data on MB097 at the AACR IO meeting held in Los Angeles.

"Although PD-L1 testing is standard in some cases, many patients end up on Keytruda without really benefiting,” said Faith ...

The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...

Ignite Proteomics announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response to ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

The US Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application ...

PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to ...

Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...

Rather, TIL have made a decisive move toward an in-licensing strategy, bringing in a bispecific antibody called SYN-2510.

Reports Q4 revenue $ $3.71M , consensus $5.47M…Bicycle Therapeutics (BCYC) is currently conducting the Phase 2/3 Duravelo-2 registrational ...

Medicenna Therapeutics Corp. shares T.MDNA are trading unchanged at $1.13.